Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
Results from two large clinical trials should cement the value of the drugs brigatinib (Alunbrig) and durvalumab (Imfinzi) in treating non-small cell lung cancer (NSCLC). The trial results, several experts said, confirm that the drugs can improve the outcomes of patients with advanced NSCLC.
-
A new test can help to improve the clinical management of women who screen positive for HPV infection during routine cervical cancer screening, an NCI-led study has shown.
-
Cancer researchers have trained a computer program to scan images of tissue samples to differentiate normal lung tissue from the two most common forms of lung cancer. The program also learned to detect cancer-related genetic mutations in the samples.
-
Adolescents who use pod-style e-cigarettes had higher levels of nicotine in their bodies than is typically found in adolescents who smoke conventional cigarettes, a new study has found. The study's findings are concerning for several reasons.
-
In a large clinical trial, the immunotherapy drug atezolizumab (Tecentriq), combined with a standard chemotherapy regimen, modestly increased survival in patients with advanced small cell lung cancer (SCLC). The trial is the first in more than 20 years to show a survival improvement in this cancer.
-
With the increasing reliance on advanced technologies and the rise of big data in cancer research, NCI launched the R50 Research Specialist Award to help sustain a stable workforce of experienced scientists who can take fullest advantage of these tools and resources.
-
In a small trial involving patients with slow-growing B-cell lymphoma, injecting the compound SD-101 directly into tumors (in situ vaccination) and giving low-dose radiation shrank the injected tumors and, frequently, tumors elsewhere in the body.
-
NCI has released its Fiscal Year 2020 Annual Plan and Budget Proposal. The plan represents NCI’s best professional judgement on the optimum funding needed to make the most rapid progress against cancer.
-
Certain cancer treatments can damage the heart and the cardiovascular system, a problem known as cardiotoxicity. Cardiologists and oncologists met recently to discuss strategies and future research directions for addressing these side effects.
-
Results from a clinical trial show that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) halted the growth of or shrank metastatic brain tumors in more than half of participants with melanoma that had spread to the brain.